ARK Invest's position in URGN, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| IZRL | 65,657 | $1.7M | 1.45% | #49 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-12 | IZRL | Buy | Added | 11,207 | $296K |
| 2026-10-16 | IZRL | Buy | Added | 1,438 | $50K |
| 2026-07-16 | IZRL | Sell | Trimmed | 46,096 | $1.8M |
| 2026-04-16 | IZRL | Sell | Trimmed | 14,037 | $300K |
| 2026-01-15 | IZRL | Sell | Trimmed | 8,379 | $164K |
| 2025-10-16 | IZRL | Sell | Trimmed | 12,413 | $210K |
| 2025-07-17 | IZRL | Sell | Trimmed | 30,584 | $471K |
| 2025-04-17 | IZRL | Sell | Trimmed | 5,688 | $55K |
| 2025-01-16 | IZRL | Buy | Added | 59,354 | $624K |
| 2024-10-17 | IZRL | Buy | Added | 40,225 | $516K |
| 2024-07-18 | IZRL | Sell | Trimmed | 19,908 | $331K |
| 2024-04-18 | IZRL | Buy | Added | 2,732 | $39K |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a…
See URGN's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open URGN on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.